Post hoc analysis of the relapsed/refractory subgroups
We further conducted a post hoc subgroup analysis on relapsed and refractory patients. For the relapsed subgroup, there were 55 patients; 36 were in the EPAG+tacrolimus group, and 19 were in the EPAG monotherapy group. No significant differences were detected in the baseline characteristics between patients in the EPAG+tacrolimus and EPAG monotherapy groups except for in the baseline haemoglobin level (88 (44–159) g/L for the EPAG+tacrolimus group and 68 (30-114) g/L for the EPAG monotherapy group, There were 59 refractory patients, with 40 patients in the EPAG+tacrolimus group and 19 in the EPAG monotherapy group. No significant difference was found in baseline characteristics (Supplementary Table 